Form 8-K - Current report:
SEC Accession No. 0000950170-24-018763
Filing Date
2024-02-22
Accepted
2024-02-22 16:10:12
Documents
14
Period of Report
2024-02-22
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K rlay-20240222.htm   iXBRL 8-K 44735
2 EX-99.1 rlay-ex99_1.htm EX-99.1 169058
3 GRAPHIC img175089203_0.jpg GRAPHIC 7375
  Complete submission text file 0000950170-24-018763.txt   354933

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT rlay-20240222.xsd EX-101.SCH 28268
15 EXTRACTED XBRL INSTANCE DOCUMENT rlay-20240222_htm.xml XML 4938
Mailing Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139
Business Address 399 BINNEY STREET 2ND FLOOR CAMBRIDGE MA 02139 617-370-8837
Relay Therapeutics, Inc. (Filer) CIK: 0001812364 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39385 | Film No.: 24664804
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)